Cargando…
Cariprazine in Three Special Different Areas: A Real-World Experience
Cariprazine is an antipsychotic medication which received approval from the US Food and Drug Administration for the treatment of schizophrenia in September 2015. Cariprazine is a dopamine D(3) and D(2) receptor partial agonist, with a preference for the D(3) receptor. Furthermore, although to a more...
Autores principales: | Gesi, Camilla, Paletta, Silvia, Palazzo, Maria Carlotta, Dell’Osso, Bernardo, Mencacci, Claudio, Cerveri, Giancarlo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8665865/ https://www.ncbi.nlm.nih.gov/pubmed/34908838 http://dx.doi.org/10.2147/NDT.S335332 |
Ejemplares similares
-
Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm
por: Cerveri, Giancarlo, et al.
Publicado: (2019) -
Defining effective strategies to prevent post-traumatic stress in healthcare emergency workers facing the COVID-19 pandemic in Italy
por: Carmassi, Claudia, et al.
Publicado: (2020) -
How Did COVID-19 Affect Suicidality? Data from a Multicentric Study in Lombardy
por: Gesi, Camilla, et al.
Publicado: (2021) -
Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience
por: Montes, Jose M, et al.
Publicado: (2021) -
Complicated Grief: What to Expect After the Coronavirus Pandemic
por: Gesi, Camilla, et al.
Publicado: (2020)